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Background. Huntington’s disease (HD) is the most common neurodegenerative disorder with no effective 
cure currently available. Over the past few years our research has shown that alterations in sphingolipid 
metabolism represent a critical determinant in the pathogenesis of the disease. In particular, we have provided 
the first evidence of aberrant metabolism of sphingosine-1-phosphate (S1P) in multiple disease settings 
including human post-mortem brains from HD patients. Importantly, we have also demonstrated that 
pharmacological interventions aimed at reducing S1P degradation, by inhibition S1P-Lyase (SGPL1), resulted 
beneficial in an HD cell model.  
 
Aim. In this study, we aimed to investigate whether inhibition of SGPL1 may exert therapeutic action in-vivo 
in the R6/2 HD mouse model.  
 
Results. Our results indicate that chronic administration of 0.1 mg/kg THI is safe and well tolerated in manifest 
R6/2 HD mice. The compound significantly slowed down the progressive mouse motor deficit associated with 
the worsening of the disease. Immunoblotting analysis reveals a significant increase in the levels of cortical 
post synaptic density protein PSD-95 in HD treated animals. Further analyses are in progress for establishing 
any other disease- modifying properties of the compound.  
 
Conclusion. Our preliminary data indicate that the beneficial effect of THI treatment may be likely associated 
with an increased synaptic activity. These findings further support the idea that modulation of S1P metabolism 
may represent a promising therapeutic approach for the treatment of the disease. 
 
